• Kanvas Biosciences

  Participated · Series A · May 2026

  Kanvas Biosciences develops a spatial biology platform for microbiome drug screening, discovery and manufacturing aimed at accelerating live biotherapeutics development. The company’s lead program is KAN-001, an immuno-oncology candidate for which the recent Series A will fund clinical trials. Kanvas intends to use proceeds to advance commercial partnerships alongside clinical development. Its core technology was initially developed at Cornell University and is exclusively licensed. The company is led by CEO Matthew Cheng. The articles do not report revenue, user metrics, founding year, or prior financing details.

• Handl Health

  Participated · Series A · Feb 2026

  Handl Health provides a unified analytical and operational platform that aggregates pricing, utilization, benefit, and quality data so insurance brokers, carriers, and third-party administrators can build customizable employer health plans. Its software models provider performance, optimizes care pathways, and tracks real-world outcomes, allowing employers to move away from one-size-fits-all coverage. Over the last two years the company reports identifying $113 million in savings on nearly $1 billion of healthcare spend and enabling alternative plans that cut consumer costs on shoppable procedures by 22 percent. Handl positions itself as the infrastructure layer for the next generation of network analytics and alternative plan design, leveraging AI and newly available price-transparency datasets. With fresh capital, the team plans to expand the platform’s capabilities, deepen plan analytics, and deliver more predictable pricing and improved patient care. The $14.2 million Series A brings additional resources to accelerate product development and market penetration among the 60 percent of under-retirement-age Americans covered by employer plans.

• Ventaris Surgical

  Participated · Series A · Jan 2026

  Ventaris Surgical is a privately held med-tech firm focused on improving kidney stone surgery through a novel ureteroscopic system that minimizes friction in the procedure and helps surgeons attain consistent, complete stone clearance. The company asserts that current instruments make it difficult to reliably remove all stones because of anatomical variation, stone burden, workflow constraints, and surgeon fatigue. By redesigning the toolset, Ventaris intends to boost surgical outcomes while easing surgeon workload. Headquartered in San Carlos, California, the startup is still in the clinical development stage and has not disclosed commercial revenues or user metrics. It plans to use newly raised capital to advance clinical studies and achieve key regulatory and commercial milestones. Board expansion accompanies the financing, adding Varun Gupta (Longitude Capital) and Justin Klein (Vensana Capital) alongside independent director Amir Abolfathi.

• Smartlens

  Participated · Equity · Oct 2025

  Smartlens’ flagship product, miLens, is the world’s first electronics-free soft contact lens capable of continuous intraocular pressure (IOP) measurement. The microfluidic lens pairs with the firm’s AI-powered smartphone imaging platform to capture real-time pressure data and deliver predictive analytics for glaucoma and ocular-hypertension patients. The company is running a multi-site U.S. pivotal trial and has advanced regulatory preparation, manufacturing scale-up, and clinical validation. Market demand appears strong: a Market Scope survey of 166 ophthalmic practitioners showed 96.2 % intend to adopt miLens once available. After securing FDA clearance, Smartlens plans an expedited commercial launch and expects its platform to enable earlier, data-driven interventions that could slow disease progression for the 180 million people affected by glaucoma and ocular hypertension worldwide. The recent $5.2 million bridge financing provides the capital needed to complete the clearance process and prepare for market entry.

• Delfina Care

  Participated · Series A · Jan 2025

  Delfina Care is a San Francisco-based healthcare technology company that applies AI-driven, evidence-based care to maternal and infant health. Led by CEO and founder Senan Ebrahim, MD, PhD, the company partners with diverse healthcare providers to deploy its care model. Delfina’s approach has produced measurable reductions in preterm births, NICU admissions, hypertensive disorders, and gestational diabetes among its partners’ populations. Its core product combines AI technology with provider partnerships to identify and manage high-risk pregnancies and improve outcomes. The company plans to use new funding to support national expansion, further innovate its AI technology, and deepen partnerships with healthcare providers. Financial and operating metrics such as revenue or user counts were not disclosed in the article.

No current team members are available.